Circulating miR-210 predicts survival in critically ill patients with acute kidney injury

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 7, 2011, Pages 1540-1546

  Lorenzen, Johan M ^a,b,c   Kielstein, Jan T ^c   Hafer, Carsten ^c   Gupta, Shashi K ^a,b   Kümpers, Philipp ^d   Faulhaber Walter, Robert ^c   Haller, Hermann ^c   Fliser, Danilo ^e   Thum, Thomas ^a,b  

^a Institute for Molecular and Translational Therapeutic Treatment Strategies   (Germany)

^b Clinic of Nephrology and Hypertension   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e SAARLAND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA; MICRORNA 16; MICRORNA 210; MICRORNA 320; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DOWN REGULATION; FEMALE; GENE EXPRESSION PROFILING; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; RENAL REPLACEMENT THERAPY; RNA ISOLATION; SURVIVAL; UPREGULATION;

ACUTE KIDNEY INJURY; ADULT; ANALYSIS OF VARIANCE; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CRITICAL ILLNESS; FEMALE; GENETIC MARKERS; GERMANY; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MICRORNAS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODELS; RENAL REPLACEMENT THERAPY; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME; UP-REGULATION;

EID: 79960290810     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.00430111     Document Type: Article

References (25)

1. Barrantes F, Tian J, Vazquez R, Amoateng-Adjepong Y, Manthous CA: Acute kidney injury criteria predict outcomes of critically ill patients. Crit Care Med 36: 1397-1403, 2008
2. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A: Acute Kidney Injury Network (AKIN): Report of an initiative to improve outcomes in acute kidney injury. Crit Care 11: R31, 2007
3. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, Tolwani A, Ronco C; Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) Investigators: Acute renal failure in critically ill patients: A multinational, multicenter study. JAMA 294: 813-818, 2005
4. van Rooij E, Sutherland LB, Thatcher JE, DiMaio JM, Naseem RH, Marshall WS, Hill JA, Olson EN: Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis. Proc Natl Acad Sci U S A 105: 13027-13032, 2008
5. Thum T, Galuppo P, Wolf C, Fiedler J, Kneitz S, van Laake LW, Doevendans PA, Mummery CL, Borlak J, Haverich A, Gross C, Engelhardt S, Ertl G, Bauersachs J: MicroRNAs in the human heart: A clue to fetal gene reprogramming in heart failure. Circulation 116: 258-267, 2007
6. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, Lin DW, Urban N, Drescher CW, Knudsen BS, Stirewalt DL, Gentleman R, Vessella RL, Nelson PS, Martin DB, Tewari M: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 105: 10513-10518, 2008
7. Gilad S, Meiri E, Yogev Y, Benjamin S, Lebanony D, Yerushalmi N, Benjamin H, Kushnir M, Cholakh H, Melamed N, Bentwich Z, Hod M, Goren Y, Chajut A: Serum microRNAs are promising novel biomarkers. PLoS One 3: e3148, 2008
8. Gupta SK, Bang C, Thum T: Circulating microRNAs as biomarkers and potential paracrine mediators of cardiovascular disease. Circ Cardiovasc Genet 3: 484-488, 2010
9. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, Weber M, Hamm CW, Röxe T, Müller-Ardogan M, Bonauer A, Zeiher AM, Dimmeler S: Circulating microRNAs in patients with coronary artery disease. Circ Res 107: 677-684, 2010
10. Faulhaber-Walter R, Hafer C, Jahr N, Vahlbruch J, Hoy L, Haller H, Fliser D, Kielstein JT: The Hannover Dialysis Outcome study: Comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. Nephrol Dial Transplant 24: 2179-2186, 2009
11. Fliser D, Kielstein JT: Technology insight: Treatment of renal failure in the intensive care unit with extended dialysis. Nat Clin Pract Nephrol 2: 32-39, 2006
12. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H, Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med 22: 707-710, 1996
13. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: A severity of disease classification system. Crit Care Med 13: 818-829, 1985
14. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G; International Sepsis Definitions Conference: 2001 SCCM/ESICM/ACCP/ ATS/SIS International Sepsis Definitions Conference. Intensive Care Med 29: 530-538, 2003
15. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P; Acute Dialysis Quality Initiative workgroup: Acute renal failure-Definition, outcome measures, animal models, fluid therapy and information technology needs: The Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8: R204-R212, 2004
16. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP: Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249-264, 2003
17. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, Kok WE, Pinto YM: MiR423-5p as a circulating biomarker for heart failure. Circ Res 106: 1035-1039, 2010
18. Kümpers P, Hafer C, David S, Hecker H, Lukasz A, Fliser D, Haller H, Kielstein JT, Faulhaber-Walter R: Angiopoietin-2 in patients requiring renal replacement therapy in the ICU: Relation to acute kidney injury, multiple organ dysfunction syndrome and outcome. Intensive Care Med 36: 462-470, 2010
19. Lukasz A, Hellpap J, Horn R, Kielstein JT, David S, Haller H, Kumpers P: Circulating angiopoietin-1 and angiopoietin-2 in critically ill patients: Development and clinical application of two new immunoassays. Crit Care 12: R94, 2008
20. Lorenzen JM, Hafer C, Faulhaber-Walter R, Kümpers P, Kielstein JT, Haller H, Fliser D: Osteopontin predicts survival in critically ill patients with acute kidney injury. Nephrol Dial Transplant 26: 531-537, 2011
21. Fasanaro P, D'Alessandra Y, Di Stefano V, Melchionna R, Romani S, Pompilio G, Capogrossi MC, Martelli F: MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosinekinase ligand Ephrin-A3. J Biol Chem 283: 15878-15883, 2008
22. Neal CS, Michael MZ, Rawlings LH, Van der Hoek MB, Gleadle JM: The VHL-dependent regulation of microRNAs in renal cancer. BMC Med 8: 64, 2010
23. D'Alessandra Y, Devanna P, Limana F, Straino S, Di Carlo A, Brambilla PG, Rubino M, Carena MC, Spazzafumo L, De Simone M, Micheli B, Biglioli P, Achilli F, Martelli F, Maggiolini S, Marenzi G, Pompilio G, Capogrossi MC: Circulating microRNAs are new and sensitive biomarkers of myocardial infarction. Eur Heart J 31: 2765-2773, 2010
24. Bai X, Fischer S, Keshavjee S, Liu M: Heparin interference with reverse transcriptase polymerase chain reaction of RNA extracted from lungs after ischemia-reperfusion. Transpl Int 13: 146-150, 2000
25. Wiesen JL, Tomasi TB: Dicer is regulated by cellular stresses and interferons. Mol Immunol 46: 1222-1228, 2009